Mark Rus

BOSTON — (BUSINESS WIRE) — Delix Therapeutics, Inc., a new CNS-focused drug discovery company, today announced the appointment of veteran biotech industry executive Mark Rus as Chief Executive Officer. Mr. Rus was previously an Advisor at Atlas Venture, where he led an early-stage neuropsychiatry focused effort. Prior to Atlas, Mark was Group Vice President of Neuroscience at Shire Pharmaceuticals (now part of Takeda Pharmaceuticals).

To learn more, please visit Business Wire to read the full press release.

--

--

Mark Rus

Mark Rus

Mark Rus is the Chief Executive Officer of Delix Therapeutics, Inc., a CNS-focused drug discovery company located in Boston, MA.